Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04640779

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:42.286474+00:00

Published At

2026-01-06T00:00:00+00:00

Record Updated At

2026-01-06

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Recurrent Histiocytic and Dendritic Cell Neoplasm", "Recurrent Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Refractory Histiocytic and Dendritic Cell Neoplasm", "Refractory Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-01-06"

protocolSection.identificationModule.nctId

"NCT04640779"

protocolSection.identificationModule.officialTitle

"Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple Myeloma"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Recurrent Histiocytic and Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
• Recurrent Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
• Refractory Histiocytic and Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
• Refractory Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.